Vertex’s 22% Sales Growth And Pipeline Gives Biotech Something To Smile About
Sickle Cell Therapy Could Be Next Blockbuster
Vertex's full year results exceeded expectations, and could help revive flagging faith in biotech stocks. • Source: Getty Images 
